Lundbeck and Takeda Form Alliance

H. Lundbeck A/S and Takeda Pharmaceutical Company Limited have announced a strategic alliance for the exclusive co-development and co-commercialization in the United States and Japan of several compounds in Lundbeck's pipeline for the treatment of mood and anxiety disorders.

The partnership will initially focus on co-development and co-commercialization of the two most advanced compounds in Lundbeck's pipeline for mood and anxiety disorders. Assuming approvals, the companies plan to co-promote the compounds in the United States and Japan.

Under the terms of the agreement, Lundbeck will receive an initial payment of EUR 28 million and potentially a maximum of EUR 244 million in additional development milestone payments. Takeda and Lundbeck will jointly complete the development programmes, with Takeda booking the total sales and funding the majority of the remaining development activities. Lundbeck will receive a share of the revenue generated in the US and Japan as well as royalty payments on Takeda's share of revenues.

"We are delighted to have reached an agreement with one of the strongest global players in central nervous system research," says Yasuchika Hasegawa, President of Takeda.

Dr. Claus Braestrup, President and CEO of Lundbeck, says: "This agreement provides a unique opportunity for Lundbeck to build a commercial presence both in the US and in Japan with the support of a strong partner, while we continue to utilize our own European and international platform outside the US and Japan to commercialize the compounds."

For further information please contact:

Caroline Broge,

Media Relations Manager

Tel: +45 36 43 26 38

Email: brog@lundbeck.com

Or visit: www.lundbeck.com